A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer-Reference-Cited by-同舟云学术

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer

Published:2013-01 Issue:1 Volume:24 Page:145-152
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Kaye S.B.,Poole C.J.,Dańska-Bidzińska A.,Gianni L.,Del Conte G.,Gorbunova V.,Novikova E.,Strauss A.,Moczko M.,McNally V.A.,Ross G.,Vergote I.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/1/145/13789326/mds282.pdf

Reference28 articles.

1. Estimates of the cancer incidence and mortality in Europe in 2006;Ferlay;Ann Oncol,2007

2. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer;du Bois;J Natl Cancer Inst,2003

3. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study;Ozols;J Clin Oncol,2003

4. Overview of epithelial cancer management. Part II Treatment of recurrent disease;Harries;Lancet Oncol,2002

5. Current treatment and clinical trials in ovarian cancer;Han;Expert Opin Invest Drugs,2010

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions;Cancer and Metastasis Reviews;2023-06-27

2. Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective;Cancer Drug Resistance;2022

3. Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies;Current Oncology;2021-11-21

4. Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer;Medicine;2021-08-13

5. Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores;ESMO Open;2021-08